Novocure is a commercial-stage oncology company dedicated to the advancement of TTF therapy for patients with solid tumors. Our company pioneered the concept that the electric properties of cells can be used as an effective target for an anti-neoplastic therapy. Founded by Dr. Yoram Palti in 2000, Novocure has grown to become a global organization with employees in six countries. We have been fortunate throughout our expansion to attract a world class team with a shared passion to provide cancer patients with a new treatment option. Novocure is headquartered in the Jersey Isle. Novocure’s US operations are based in Portsmouth, NH and the company maintains a research facility in Haifa, Israel.